(NASDAQ: EVGN) Evogene's forecast annual revenue growth rate of -56.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,714.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,548.07%.
Evogene's revenue in 2026 is $5,082,000.On average, 3 Wall Street analysts forecast EVGN's revenue for 2026 to be $19,115,087, with the lowest EVGN revenue forecast at $18,365,476, and the highest EVGN revenue forecast at $19,681,654.
In 2027, EVGN is forecast to generate $32,451,194 in revenue, with the lowest revenue forecast at $31,178,599 and the highest revenue forecast at $33,410,000.